Autres langues Incannex Healthcare Inc.

Actions

IXHL

US45333F1093

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 14/06/2024			Varia. 5j.	Varia. 1 janv.
3,32 ^USD	+5,40 %		+2,15 %	-28,45 %

30/05	Incannex Healthcare Inc. annonce le début du dosage des patients dans le cadre du protocole de l'essai clinique de phase 2/3 RePOSA visant à évaluer le médicament IHL-42X chez les patients souffrant d'apnée obstructive du sommeil	CI
15/05	Incannex Healthcare Inc. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	30/05
Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	30/05
Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	15/05
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder	07/05
Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	07/05
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)	01/05
Incannex Healthcare Inc. Quarterly Update, Q1 2024	16/04
Incannex Healthcare Inc. Announces CFO Changes	05/03
Incannex Healthcare Inc. Announces Executive Changes	05/03
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28/02
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28/02
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA	16/02
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	16/02
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N	16/02
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
Clarion Clinics Open for Psychedelic-Assisted Treatments	01/02
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	24/01
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	24/01
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	18/01
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder	18/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Incannex Healthcare Inc.

Actions

IXHL

US45333F1093

Autres langues

Filtres